Dear IL-17 researchers,
IL-17 is now acknowledged as a key mediator of various chronic inflammatory diseases. Based on a wealth of data from clinical and basic research, 5 different therapies that target the IL-17/Th17 axis are already licensed, and even more are currently in development.
To obtain a deeper understanding of diseasedriving molecular networks and to identify novel therapeutic approaches, the intense collaboration of basic researchers and expert clinicians is essential.
Therefore, we look forward to welcoming you at the 3rd IL-17 Summit to share your experience, ideas and latest findings on IL-17 at this outstanding interdisciplinary meeting in Munich. Extending the scope of our congress at this year’s meeting, we are also going to cover the fascinating field of IL-1 -mediated autoinflammation and feature lectures on exciting new technologies that are going to revolutionize future research.
Burkhard Becher, Dirk Föll, Ulrich Mrowietz, Ulf Müller-Ladner, Ulf Panzer, Ari Waisman
Scientific Steering Committee
Please send email to firstname.lastname@example.org, download the registration form or go to our online Registration.
Deadline for registration is Friday, December 21, 2018
Registration fee: 50 € (includes hotel room for one night). If no accommodation is needed, registration fee is 25 €.
Sheraton Munich Arabellapark Hotel
Arabellastr. 5 · 81925 München
(2 min from U4 Arabellapark)
Call for posters
We will accept approx. 40 posters.
Poster topic should be clinic or basic research work related to IL-17 or IL-1.
Please send poster abstract (max 250 words) to
Deadline for abstract submission is Friday, December 14, 2018
Abstracts will be reviewed by the steering committee. First authors of accepted abstracts
will receive full travel & accommodation costs by Novartis.
Poster presenters will be selected on a first come first serve basis.